Drugs Ther Perspect (2018) 34:288 https://doi.org/10.1007/s40267-018-0526-y CORRECTION Correction to: Dinutuximab beta in high-risk neuroblastoma: a proﬁle of its use 1 1 Kate McKeage Katherine A. Lyseng-Williamson Published online: 6 June 2018 Springer International Publishing AG, part of Springer Nature 2018 Correction to: Drugs Ther Perspect https://doi.org/10.1007/s40267-018-0522-2 The Acknowledgements section on the last page should read: ‘‘The manuscript was reviewed by: P.F. Ambros, Chil- dren’s Cancer Research Institute, St. Anna Kinderkrebs- forschung, Vienna, Austria; F.H. Felix, Pediatric Cancer Center, Hospital Infantil Albert Sabin, Fortaleza, Brazil; R. Kebudi, Division of Pediatric Hematology-Oncology, Cerrahpas ¸ a Medical Faculty & Oncology Institute, Istan- bul, Turkey; H.B. Lindsay, Pediatric Hematology/Oncol- ogy, Baylor College of Medicine, Houston, TX, USA; J. Morales, Pharmacy Department, Hospital Dr Luis Calvo Mackenna, Santiago, Chile. During the peer review pro- cess, EUSA Pharma (UK) Limited, the marketing-autho- rization holder of dinutuximab beta, was offered an opportunity to provide a scientiﬁc accuracy review of their data. Changes resulting from comments received were made on the basis of scientiﬁc and editorial merit. The original article has been corrected. The original article can be found online at https://doi.org/10.1007/ s40267-018-0522-2. & Katherine A. Lyseng-Williamson email@example.com Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand
Drugs & Therapy Perspectives – Springer Journals
Published: Jun 6, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera